Patients presenting with severe left ventricular (LV) dysfunction undergoing coronary artery bypass surgery are a difficult subset to treat and are at an increased risk of perioperative morbidity and mortality. Current treatment options for this high-risk group of patients include intensive medical therapy, surgical revascularization, ventricular remodeling, and heart transplantation. Medical treatment alone is problematic because of limited long-term survival.\(^1,2\) As the proportion of high-risk patients for cardiac surgery increases, use of intra-aortic balloon counterpulsation (IABP) has increased, especially as part of preoperative therapy. The routine preoperative use of IABP in high-risk patient population has had favorable reports from some investigators.

The Coronary Artery Surgery Study (CASS) study demonstrated that only 38% of medically treated patients (EF < 35%) were alive and free of moderate or severe limitation of symptoms after 5 years of treatment.\(^1\) Intra-aortic balloon pump (IABP) is widely used to provide circulatory support for patients experiencing hemodynamic instability due to myocardial infarction, cardiogenic shock, or in very high risk patients undergoing angioplasty or coronary artery bypass grafting. IABP was first employed over three decades ago as a treatment of last resort for terminally ill patients suffering from cardiogenic shock.

The American College of Cardiology/American Heart Association guideline indications for IABP use in acute myocardial infarction include preparation for angiography and revascularization in cardiogenic shock that has not quickly reversed, acute mitral regurgitation or ventricular septal defect, refractory post-MI angina, refractory ventricular arrhythmias with hemodynamic instability, poor left ventricular function or recurrent ischemia.\(^4\) Beneficial effects of preoperative intra-aortic balloon pump treatment on outcome and cost in high-risk patients who have coronary artery bypass grafting have been demonstrated in various studies.\(^5\) Cardiopulmonary bypass time was shorter in the IABP group and the incidence of postoperative low cardiac output was also significantly lower in them. Intubation time, length of stay in the intensive care unit and hospital stay were also shorter in the IABP group.\(^5,6\) Even in high-risk off pump coronary artery bypass graft surgery routine, preoperative insertion of IABP reduced the incidence of acute renal failure and helped in earlier discharge of the patients. However there was no difference in mortality rates in those who had IABP when compared with patients without the IABP.\(^7\)

Use of IABP is associated with certain complications, including peripheral ischemia, infection, and hematological derangements. The incidence of vascular complications reported in literature ranges from 8.7 to 20%.\(^8\) There are reports of in-hospital mortality being significantly lower in patients treated preoperatively with IABP compared with patients treated postoperatively.\(^9\) There is a clear relationship between duration of treatment and balloon-related complications. Independent risk factors for balloon-related complications are longer treatment time, acute myocardial infarction, age over 65 years and ejection fraction less than 30%. The benchmark registry included worldwide prospectively collected data from 203 hospitals on 16909 patients, who received IABP between June 1996 and August 2000.\(^10\) The registry reported overall IABP-related morbidity of 2.6% and IABP-related mortality of 0.05%. Female sex, old age and peripheral vascular disease were reported as independent predictors of major complications. Severity of coronary artery disease and left ventricular aneuryism surgery were found to be an independent risk factor. Many of these patients had unstable angina, hemodynamic instability and cardiac arrhythmias as indications of IABP insertion, which were also found to be independent risk factors for vascular complications. These factors reflect the severity of underlying cardiac dysfunction. Davoodi et al.\(^11\) have interesting observations. In their study involving over eight hundred high-risk cases the use of IABP was associated with prolonged hospital stay and independently predicted mortality at 1 month.

The decision to insert IABP may be individualized and best left to the treating physician as there are varying reports indicating differing outcomes.

**REFERENCES**


K. JAI SHANKAR
Institute of Cardiovascular Diseases, Madras Medical Mission, 4 A, Dr. J.J. Nagar, Mogappair, Chennai 600 037, India.
E-mail: drkjs68@yahoo.com

ORIGINAL CONTRIBUTIONS

ROLE OF QUANTITATIVE ENDOTRACHEAL ASPIRATE AND CULTURES AS A SURVEILLANCE AND DIAGNOSTIC TOOL FOR VENTILATOR ASSOCIATED PNEUMONIA: A PILOT STUDY

SHALINI NAIR, NAGAMANI SEN, JOHN VICTOR PETER1, JOHN PRAKASH RAJ, K. N. BRAHMADATHAN2

ABSTRACT

BACKGROUND: Accurate diagnosis and appropriate treatment of ventilator associated pneumonia (VAP) is crucial for good outcomes. Endotracheal suctioning is performed in ventilated patients as part of routine care and for tracheal toileting.

AIM: We evaluated if quantitative endotracheal aspirate (ETA) was a suitable alternative to bronchoalveolar lavage (BAL) for suspected VAP. In addition we assessed if surveillance ETA guided antibiotic selection for subsequent VAP.

SETTING AND DESIGN: Prospective study in the surgical intensive care unit (ICU) of a tertiary hospital in India.

MATERIALS AND METHODS: Two hundred consecutive patients with mean (standard deviation) APACHE II score of 12.3±5 and requiring mechanical ventilation beyond 48 hours underwent surveillance ETA cultures. A second ETA and BAL were performed if the patient developed features of VAP. The threshold for microbiological diagnosis of VAP was taken as 105 colony forming units/ml (cfu/ml) for ETA and 104 cfu/ml for BAL.

STATISTICAL ANALYSIS: The sensitivity and specificity of surveillance and concurrent ETA aspirate cultures were compared with BAL cultures.

RESULTS: VAP was suspected clinically and corroborated radiologically in 27/177 patients (15.3%). Although microbiological support for VAP was obtained by ETA in 19 patients, bronchoscopy was possible only in 13 patients, 8 of whom had isolates at significant threshold. Of the 16 organisms isolated from BAL, 11 were of significant threshold with 9/11 (82%) BAL isolates having a similar antibiogram to a concurrent ETA. Only one BAL isolate (9%), at significant threshold, was not isolated on a concurrent ETA. On the other hand just 6/11 BAL isolates (55%) had an identical antibiogram to surveillance ETA. BAL had 3 additional isolates (27%) at significant threshold not isolated on surveillance ETA.

CONCLUSIONS: Concurrent quantitative ETA could substitute BAL cultures for VAP. Surveillance ETA at 48 hours of ventilation does not appear to assist with antibiotic selection for a subsequent VAP.

Key words: Antibiogram, bronchoalveolar lavage, quantitative analysis, surveillance endotracheal aspirate, ventilator associated pneumonia

Surgical Intensive Care Unit, 1Medical Intensive Care Unit, 2Department of Microbiology, Christian Medical College and Hospital, Vellore, India

Correspondence:
Dr. J. V. Peter,
Medical Intensive Care, Christian Medical College and Hospital, Vellore-632 004, India.
E-mail: peterjohnvictor@yahoo.com.au